Zhang Ying-Yan, Wang Qi
Department of Gynaecology and Obstetrics, Beijing Huairou Maternal and Child Health Hospital, Beijing 101400, China.
Department of Obstetrics, Beijing Hospital of Obstetrics and Gynecology, Capital Medical University, Beijing 100026, China.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Dec;33(12):1645-7.
To study the clinical value of the preeclampsia risk assessment system, and to explore the preventive effect of Qiju Dihuang Oral Liquid (QDOL) on preeclampsia patients.
Totally 2 000 pregnant women in the gestational week 16 -20 were equally assigned to Group A and Group B by randomized sampling. Their preeclampsia incidence was respectively assessed by preeclampsia risk assessment system and mean arterial pressure method. Of them, 200 pregnant women at predicted high risk of preeclampsia were assigned to the control group and the treatment group, 100 in each group. All received routine treatment. Patients in the treatment group additionally took QDOL, 10 mL each time, twice daily; 2 consecutive weeks per month for totally 2 weeks; lasting for six consecutive courses or ending according to the therapeutic course. The incidence was observed and compared between the two groups.
The predicted coincidence rate of the risk assessment system was 72.3%, higher than that of mean arterial pressure method (50.5%, P < 0.05). The incidence rate of the treatment group was 32.0%, lower than that of the control group (46.0%, P < 0.05).
The preeclampsia risk assessment system was more accurate. QDOL could lower the incidence of preeclampsia as intervention.
研究子痫前期风险评估系统的临床价值,探讨杞菊地黄丸口服液(QDOL)对子痫前期患者的预防作用。
采用随机抽样法将2000例孕16 - 20周的孕妇平均分为A组和B组,分别采用子痫前期风险评估系统和平均动脉压法评估子痫前期发病率。其中,将200例预测为子痫前期高风险的孕妇分为对照组和治疗组,每组100例。两组均接受常规治疗。治疗组患者加服QDOL,每次10 mL,每日2次;每月连续服用2周,共2周;连续服用6个疗程或根据疗程结束。观察并比较两组发病率。
风险评估系统的预测符合率为72.3%,高于平均动脉压法(50.5%,P < 0.05)。治疗组发病率为32.0%,低于对照组(46.0%,P < 0.05)。
子痫前期风险评估系统更准确。QDOL作为干预措施可降低子痫前期的发病率。